Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.10
-0.01 (-0.14%)
At close: Apr 17, 2026
Market Cap1.72B +1.6%
Revenue (ttm)1.45B -4.6%
Net Income154.02M -0.1%
EPS0.63 -16.9%
Shares Out241.52M
PE Ratio11.33
Forward PEn/a
Dividend0.07 (0.93%)
Ex-Dividend DateJun 17, 2026
Volume14,600
Average Volume68,400
Open7.05
Previous Close7.11
Day's Range7.05 - 7.22
52-Week Range5.80 - 16.29
Betan/a
RSI39.23
Earnings DateMar 30, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by rad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 1,794
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2566
Full Company Profile

Financial Performance

In 2025, HKG:2566's revenue was 1.31 billion, a decrease of -4.59% compared to the previous year's 1.37 billion. Earnings were 138.41 million, a decrease of -0.14%.

Financial numbers in CNY Financial Statements